DiaMedica Therapeutics Q3 EPS $(0.21), Inline. Cash and Equivalents #34.9M

Benzinga · 2d ago
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 23.53 percent decrease over losses of $(0.17) per share from the same period last year.